Why I’m Bullish on European Market Access: The Social Contract (Part 2 of 4)

The new GLP-1 Agonists are turning out to be quite promising for addressing diabetes, obesity and other chronic conditions. So promising that many patients in Europe are <a href="https://www.ft.com/content/bbbe8543-263c-4e5b-a567-2ef05f2b3138" rel="noopener ugc nofollow" target="_blank">willing to pay out of pocket</a> for these treatments rather than wait for access for their indications through traditional reimbursement channels. In Europe there’s a general expectation that medicines are reimbursed by either private or public insurance. Could that be changing? In addition to creating <a href="https://medium.com/@nathansigworth/when-production-not-pricing-is-the-market-access-constraint-332b51381e2a" rel="noopener">initial demand shock</a> in the system, this trend of patients paying out of pocket for faster access could continue and expand as private payment for these therapies and others that can be paid for by individuals open up budgets for the more expensive cell and gene therapies that can really only be financed through insurance and other mechanisms of social solidarity. <a href="https://medium.com/@nathansigworth/why-im-bullish-on-european-market-access-glp1s-are-changing-the-social-contract-part-2-of-4-c46d6c8cdc3f">Website</a>